Publications by authors named "Christian Guido Ruf"
Article Synopsis
- - Systematic follow-up for cured testicular cancer patients began in the 1980s, driven by advancements in cisplatin-based chemotherapy and imaging technology like CT scans, with three main goals: catching recurrences early, monitoring treatment side effects, and spotting other diseases.
- - Due to the varied nature of testicular cancer, follow-up care isn't one-size-fits-all and requires risk-adjusted schedules; recent guidelines revised in 2019 simplified this to three risk groups instead of four.
- - The updated guidelines recommend using MRI instead of CT scans and abdominal ultrasounds for imaging, and they advise against using chest X-rays for seminoma patients during follow-ups.
Background: Post-chemotherapy retroperitoneal lymph node dissection (pc-RPLND) is one cornerstone in the clinical management of patients with nonseminomatous testicular germ cell tumours (GCT). A wide range of complication rates in this type of surgery is reported so far. We retrospectively evaluated the frequency of major complications by using the Clavien-Dindo classification and analysed the influence of various clinical factors on complication rates in pc-RPLND.
View Article and Find Full Text PDFPurpose: Leydig-cell tumours (LCT) of the testis are poorly understood clinically. The aim of this report is to analyse the clinical characteristics of LCT in a large patient sample and to compare these findings with corresponding data of germ-cell tumours (GCT).
Methods: In a sample of 208 patients treated during 1995-2017 in 33 institutions, the following characteristics were registered: age, presenting symptoms, primary tumour size, testis-sparing surgery (TSS) or orchiectomy, malignancy, laterality, medical history, and outcome.
Purpose: Clinical stage (CS) 1 testicular seminoma is cured in almost 100% of cases following either retroperitoneal radiotherapy, carboplatin monotherapy, or surveillance strategies. Little is known about potential long-term effects of carboplatin. We, therefore, examined late sequelae of this drug in seminoma patients.
View Article and Find Full Text PDFPurpose: Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers of testicular germ cell tumors (GCTs) and are applicable toward both seminoma and nonseminoma. We sought to confirm the usefulness of this test as a novel biomarker for GCT.
Patients And Methods: In a prospective, multicentric study, serum samples of 616 patients with testicular GCTs and 258 male controls were examined for serum levels of miRNA-371a-3p (miR levels) by quantitative polymerase chain reaction.